Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sixty-six patients with portal hypertension and esophageal varices due to liver cirrhosis were randomized to receive either 5% ethanolamine oleate (EO) or 5% EO plus 1% polidocanol (EOP) as a sclerosant for endoscopic injection sclerotherapy (EIS). The two groups were well matched with regard to age, sex and the severity of liver disease. In no patient in the two groups was there any major complication, such as esophageal perforation or esophageal bleeding. Eradication of esophageal varices was attained with an average of 4.7 and 4.3 sessions of endoscopic injection sclerotherapy in the ethanolamine oleate and polidocanol groups, respectively. Data on one patient in the ethanolamine oleate group had to be excluded because he left the hospital after 2 sessions of endoscopic injection sclerotherapy. Esophageal ulcers occurred earlier in the polidocanol group (after an average of 2.8 weeks) than in the ethanolamine oleate group (3.8 weeks), the difference being statistically significant (P < 0.01). The rate of occurrence of esophageal stricture requiring more than 2 sessions of bougienage was significantly (P < 0.01) higher in the polidocanol group (16/33, 48%) than in the ethanolamine oleate group (4/32, 12%). This study suggests that the two sclerosants have equal efficacy for treating patients with esophageal varices. With polidocanol there was ulceration and stricture in the distal esophagus.
 ...
PMID:Comparative effects of 5% ethanolamine oleate versus 5% ethanolamine oleate plus 1% polidocanol for sclerosing esophageal varices. 148 69

In 17 compensated liver cirrhosis and 8 chronic hepatitis cases (no histories of cardiac or pulmonary disease), wedged hepatic venous pressure (WHVP), hemodynamics, and pulmonary function were measured and their clinical significance and interrelations evaluated. Both diseases were comparatively analyzed. WHVP was determined by wedging a catheter from the right femoral vein into the right hepatic vein. Hemodynamics was measured with a Swan-Ganz catheter. Spirography, flow-volume curve, closing-volume curve and pulmonary diffusion capacity were measured and aortic blood gas analyzed to assess pulmonary function. Esophageal endoscopy was used to diagnose the presence or absence of esophageal varices. The results showed that the group of liver cirrhosis patients featured elevated WHVP and a hyperhemodynamic pattern and a positive correlation between WHVP on the one hand and cardiac index and right left ventricle stroke work indexes on the other; there was a negative correlation between WHVP and the systemic vascular resistance and pulmonary vascular resistance indexes. The results showed an increase in oxygen consumption in the group of patients with esophageal varices. In all chronic hepatitis cases, findings were normal. Pulmonary function was characterized by abnormal %VC, PaO2, and pulmonary diffusion capacity in both groups along with abnormal PaCO2 in the liver cirrhosis group; no significant differences were noted between the two groups. These results indicate that liver cirrhosis elevates intarahepatic pressure, affecting systemic hemodynamics and resulting in a circulatory distribution disorder, leading to right and left ventricle overload and a decline in potential cardiac function. The results also indicated that mild pulmonary function disorder can occur as early in a state of chronic hepatitis.
 ...
PMID:[Studies on wedged hepatic venous pressure, hemodynamics and pulmonary function in patients with chronic liver disease, with reference to the differences between liver cirrhosis with chronic hepatitis]. 191 74

The present trial was carried out to determine the usefulness of H2-receptor antagonist drug therapy for the prevention of esophageal bleeding and esophageal varices in patients who underwent sclerotherapy. According to randomization, out of the 58 patients, 28 received, along with the usual standard therapy, ranitidine and 30 received placebo. Ranitidine, 50 mg, was administered intravenously over a period of 3 days every 8 hours, and then 150 mg of ranitidine was given per os in the evening for one month. For improvement of hemostasis and during the elective sclerotherapies, 1% polidocanol was used as the sclerosant. During each puncture, 2 ml was injected. Injections were paravasal and intravasal. After sclerotherapy, endoscopic examinations were carried out on the third day and one month later. Necrosis was noted in 42% of the patients and esophageal mucosal inflammation in 26%. Esophageal ulcers did not occur. There was no statistically significant difference between the two groups in terms of age, sex ratio, cause of liver cirrhosis, and the Child's classification. The size of the esophageal varices had no effect on the development of esophageal mucosal changes in correlation with the quantity of sclerosant. The comparison of the two groups of patients, sclerosed for hemorrhage and sclerosed electively, showed no statistically significant difference regarding esophageal mucosal changes. No differences between the ranitidine and placebo groups of patients were observed in this indication. It can be concluded that esophageal mucosal changes probably arise as a consequence of the sclerosant, its concentration, quantity and mode of application.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Prophylactic administration of ranitidine after sclerotherapy of esophageal varices. 193 95

Results of 287 transthoracoabdominal esophageal transections (Sugiura procedure), 125 transthoracic esophageal transections, 48 transabdominal esophageal transections, and 58 other nonshunting operations performed during the past 25 years were analyzed. Overall operative mortality rate was 5.0% (26/518); however, it was observed only in patients with liver cirrhosis (7.0%) and was higher in emergency cases (23.3%) and patients classified Child C (17.1%). Two hundred two patients died during the follow-up period, which lasted 24 years; 33 patients died of rebleeding, 89 of hepatic failure, 65 of hepatoma, and 35 of other causes. Cumulative survival rates of patients after non-shunting operations differed significantly according to the nature of the original diseases and the severity of liver damage. The cumulative survival rate at 10 years in patients with extrahepatic portal obstruction was 90.7%, 77.6% in idiopathic portal hypertension, and 33.0% in liver cirrhosis and at 20 years, 85.6%, 37.9%, and 8.1% respectively. The cumulative survival rate at 5 years in patients classified Child A was 88.7%, 77.7% in Child B, and 39.5% in Child C, and at 10 years, 73.4%, 45.3%, and 14.1%, respectively. Esophageal transection can be performed safely and is recommended in patients classified Child A or B. Patients in Child C should be treated by endoscopic sclerotherapy and other conservative measures.
 ...
PMID:Twenty-five-year experiences with esophageal transection for esophageal varices. 281 21

Hemorrhage from esophageal varices is a serious complication of portal hypertension and cirrhosis, as evidenced by a 50-60% mortality rate and a 40-60% rate of recurrent hemorrhage. Esophageal injection sclerosis (EIS) has emerged as the preferred mode of therapy for esophageal hemorrhage and in most respects is superior to surgical portacaval shunt and medical therapy. EIS controls variceal bleeding acutely in 85-95% of cases and results in the long-term obliteration of varices in 60-80% of patients. EIS decreases the time the patient spends in the hospital, reduces the amount of blood transfused, and may prolong the patient's survival. Complications of ulceration and stenosis can be minimized by proper choice of agent and by manipulating the volume and concentration of sclerosing agent, the interval between sessions, and the pattern of injections within the esophagus. EIS is both effective and reasonably safe for the acute and long-term management of esophageal variceal hemorrhage and can easily be performed at most medical centers in this country.
 ...
PMID:Esophageal injection sclerosis. 329 92

During the past 6 years, 25 consecutive patients with esophageal variceal hemorrhage were treated by esophageal endosclerosis (direct injection of varices with a sclerosing agent). The primary disease in the 25 children was portal vein thrombosis (11 patients), biliary atresia (nine patients), and hepatic cirrhosis from cystic fibrosis (three patients), alpha 1-antitrypsin deficiency (one patient), and neonatal hepatitis (one patient). Thirteen patients were treated during acute, major variceal hemorrhage. Esophageal endosclerosis was repeated at regular intervals until all esophageal varices were obliterated. Twenty-one patients completed therapy. Four patients died: one of a complication of therapy and three of the primary disease. Other than the one death, complications were minor. Recurrent esophageal variceal hemorrhage has not been encountered in follow-up from 9 months to 6 years after completion of therapy.
 ...
PMID:Esophageal endosclerosis in children. 387 48

Haemorrhage from oesophageal varices is a serious and feared complication of liver cirrhosis. One hundred and five patients treated for their first major variceal haemorrhage (VH) 1976-1979 were reviewed. Conventional therapy in a material with 60% Child class C patients with alcoholic cirrhosis resulted in a 50% first bleeding and a 36% readmission mortality with a one year survival of 30%. The conclusion was that the management schedule could be improved and that endoscopic sclerotherapy (ST) should be further evaluated. Conservative therapy and the addition of emergency and serial ST was compared in a prospective controlled trial in 107 unselected patients with major VH. Two-thirds belonged to Child's class C and 90% had alcoholic cirrhosis. Initial control of VH was obtained in 90% of all patients and the admission mortality was about 30%. The causes of mortality were mainly VH in 50 conservatively treated patients and hepatic failure and to VH unrelated causes in the ST-group (57 patients). Supplementary ST, a median of 6 sessions, succeeded in eradication of the varices in 34 of the 41 ST-patients discharged, failure was due to early death or continued alcoholism. Varices recurred in 5 patients during a 2-year follow-up. The number of rebleeds per observation month was overall decreased 3.6 times in the ST-group, but the survival was not prolonged. The effect of initial and serial ST on the mediastinal portalsystemic collaterals was investigated prospectively in 26 patients by repeated selective percutaneous transhepatic portography (PTP) and endoscopy. PTP was performed immediately prior to, and just after the first ST, showing reduced or inhibited contrast filling of oesophageal varices delineated on the pre-ST films in three-fourth of the patients. In 21 patients, follow-up PTP was carried out a median of 8 months later, when the varices were eradicated by serial ST. In 17 patients PTP supported the endoscopic estimation of variceal eradication, one patient was found to have residual varices. These patients were followed for a year, two patients developed recurrent varices. This study showed that submucosal oesophageal varicose veins can be efficiently eradicated by serial ST with a low recurrence rate. Oesophageal necrosis with delayed perforation intervened in 4% of our ST-patients with fatal outcome. Complications were noted in 30% of the patients treated with ST, and were major in 18%, mainly ulcerations with bleeding and transmural necrosis. Strictures encountered in 15% of the patients were easily treated. Oesophageal manometry was performed in 31 patients.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Endoscopic sclerotherapy of oesophageal varices. A clinical study. 389 6

Percutaneous transhepatic obliteration and surgical stapling transection of the oesophagus with the EEA gun were compared prospectively in the treatment of uncontrolled oesophageal variceal haemorrhage unresponsive to conservative measures. Twenty patients with cirrhosis, with a patient portal vein and who were considered suitable for general anaesthesia and surgery, were randomised to two treatment groups (10 patients each). Immediate arrest of haemorrhage was achieved in 17 patients (nine surgery, eight obliteration). In one other patient, stapling transection succeeded where attempted transhepatic obliteration failed, and in another patient obliteration succeeded where attempted transection had failed. One patient continued to bleed and died following attempts at both procedures. Two other patients also died in hospital, without rebleeding following surgery. Variceal rebleeding during the same hospital admission occurred in two patients in the obliteration group and in none after surgery. Oesophageal stapling transection compares very favourably with a non-surgical technique such as transhepatic obliteration of varices in the emergency treatment of uncontrolled variceal haemorrhage in patients with moderate liver failure.
 ...
PMID:Randomised, controlled study of transhepatic obliteration of varices and oesophageal stapling transection in uncontrolled variceal haemorrhage. 660 67

The portosystemic collateral channels that can develop in portal hypertension are numerous, widespread, and varied in appearance. The reported prevalences of varices at each anatomic site vary according to the diagnostic modality used. Dynamic computed tomography (CT) performed with a bolus of contrast material demonstrates collateral vessels with exquisite detail. On CT scans, varices appear as well-defined found, tubular, or serpentine structures that are smooth, have homogeneous attenuation, and enhance with contrast material to the same degree as adjacent vessels. In 60 consecutive patients with varices and evidence of cirrhosis, the most common portosystemic collateral channels were coronary venous collateral vessels in the lesser omentum, seen in 80% of cases. Esophageal, paraumbilical, abdominal wall, perisplenic, retrogastric, paraesophageal, omental, retroperitoneal-paravertebral, and mesenteric varices were also found, along with spontaneous splenorenal and gastrorenal shunts. Knowledge of the CT appearance and the prevalence of varices at each anatomic site will improve diagnostic accuracy.
 ...
PMID:Varices in portal hypertension: evaluation with CT. 762 66

A total of 72 patients were operated for bleeding esophageal varices over five years. Cause of portal hypertension was cirrhosis in 33, Schistosomal fibrosis in 23 and a combination of the two diseases in 3 cases. Biopsy was not available in 13 patients. Fifty-eight patients were child grade A and B, while 14 patients were grade C. Overall, there were 16 hospital deaths (22.2%) and 28 patients had complications (38.8%). Specifically, Hassab's operation was done in 40 patients with 12.5% mortality and 11.7% incidence of rebleeding. Hassab's operation plus esophageal transection in 13 patients was associated with 46.1% mortality and no incidence of rebleeding. Warren's splenorenal shunt, done in 11 patients, was accompanied by 1 (9%) death and no incidence of rebleeding. Mortality rate increased significantly when esophageal transection was added to Hassab's operation. It is concluded that for low risk patients being operated electively, Warren's shunt is an acceptable alternative to Hassab's operation which is better suited to emergency situations. Esophageal transection should not be added to Hassab's operation because this increases the mortality.
 ...
PMID:Surgery for bleeding esophageal varices. 773 Oct 86


1 2 3 4 5 Next >>